These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3651536)

  • 21. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1990 Apr; 263(14):1896. PubMed ID: 2313862
    [No Abstract]   [Full Text] [Related]  

  • 22. The Osler's view: Treating comorbid bipolar disorder and obsessive-compulsive disorder.
    Amerio A; Tonna M; Odone A; Ghaemi SN
    Aust N Z J Psychiatry; 2017 Sep; 51(9):944-945. PubMed ID: 28747073
    [No Abstract]   [Full Text] [Related]  

  • 23. Pentagastrin has panic-inducing properties in obsessive compulsive disorder.
    de Leeuw AS; Den Boer JA; Slaap BR; Westenberg HG
    Psychopharmacology (Berl); 1996 Aug; 126(4):339-44. PubMed ID: 8878350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transient lesion in the splenium of the corpus callosum, possibly due to carbamazepine.
    Narita H; Odawara T; Kawanishi C; Kishida I; Iseki E; Kosaka K
    Psychiatry Clin Neurosci; 2003 Oct; 57(5):550-1. PubMed ID: 12950714
    [No Abstract]   [Full Text] [Related]  

  • 26. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo.
    Jenike MA; Baer L; Summergrad P; Minichiello WE; Holland A; Seymour R
    Am J Psychiatry; 1990 Jul; 147(7):923-8. PubMed ID: 2192564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.
    Dougherty DD; Corse AK; Chou T; Duffy A; Arulpragasam AR; Deckersbach T; Jenike MA; Keuthen NJ
    Int J Neuropsychopharmacol; 2015; 18(2):. PubMed ID: 25637377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New findings in obsessive-compulsive disorder.
    Kim SW; Dysken MW
    Minn Med; 1989 Feb; 72(2):91-3, 110. PubMed ID: 2651867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder.
    Frenkel A; Rosenthal J; Nezu A; Winston A
    Mt Sinai J Med; 1990 Nov; 57(6):348-52. PubMed ID: 2079952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chlorimipramine therapy for obsessive-compulsive neurosis.
    Ananth J; Solyom L; Bryntwick S; Krishnappa U
    Am J Psychiatry; 1979 May; 136(5):700-1. PubMed ID: 434251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of obsessive-compulsive disorder with ECT.
    Mellman LA; Gorman JM
    Am J Psychiatry; 1984 Apr; 141(4):596-7. PubMed ID: 6703146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.
    Fontaine R; Chouinard G
    J Clin Psychopharmacol; 1986 Apr; 6(2):98-101. PubMed ID: 3517083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Schizophrenic with obsessive-compulsive disorder or symptoms].
    Doubremelle C; Millet B; Olie JP
    Encephale; 2000; 26(2):81-8. PubMed ID: 10858921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of obsessive-compulsive neurosis with clomipramine (Anafranil).
    Ananth J
    J Int Med Res; 1977; 5 Suppl 5():38-41. PubMed ID: 598604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous clomipramine for obsessive-compulsive disorder.
    Koran LM; Faravelli C; Pallanti S
    J Clin Psychopharmacol; 1994 Jun; 14(3):216-8. PubMed ID: 8027426
    [No Abstract]   [Full Text] [Related]  

  • 38. Monoamine oxidase inhibitors in obsessive-compulsive disorder.
    Jenike MA; Surman OS; Cassem NH; Zusky P; Anderson WH
    J Clin Psychiatry; 1983 Apr; 44(4):131-2. PubMed ID: 6833198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.
    Eriksson T
    Int Clin Psychopharmacol; 2007 Jan; 22(1):57-61. PubMed ID: 17159461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiobsessional and antidepressant effects of clomipramine in the treatment of obsessive-compulsive disorder.
    Insel TR; Alterman I; Murphy DL
    Psychopharmacol Bull; 1982 Oct; 18(4):115-7. PubMed ID: 7156271
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.